

**Reference Number:** FOI202223/462  
**From:** Commercial  
**Date:** 13 December 2022  
**Subject:** Incidence and treatment of Asthma

- Q1 How many patients have been treated (for any condition) in the last 4 months with:
- Benralizumab
  - Dupilumab
  - Omalizumab
  - Reslizumab
  - Mepolizumab
  - Tezepelumab
- Q2 Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:
- Age 6-11
  - Age 12-17
  - Age 18 and above
- Q3 How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with :
- Dupilumab
  - Omalizumab
- A1 - Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.
- A3